LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Начало・Списък с акции・Cogent Biosciences Inc

Cogent Biosciences Inc

Затворен

33.54 -0.86

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

33.39

Максимум

34.74

Ключови измерители
By Trading Economics
Приходи	-7.4M -81M
EPS	-0.5
Марж на печалбата	-1,582.642
Служители	205
EBITDA	-11M -83M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+20.13% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.5B 4.6B
Предишно отваряне	34.4
Предишно затваряне	33.54

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

4.88 / 5.87 Подкрепа & съпротива

Cogent Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.11.2025 г., 17:45 ч. UTC

Печалби

Значими двигатели на пазара

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14.11.2025 г., 17:31 ч. UTC

Печалби

Значими двигатели на пазара

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14.11.2025 г., 16:15 ч. UTC

Значими двигатели на пазара

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

14.11.2025 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14.11.2025 г., 23:02 ч. UTC

Пазарно говорене

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14.11.2025 г., 22:35 ч. UTC

Печалби

Придобивния, сливания и поглъщания

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14.11.2025 г., 22:32 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14.11.2025 г., 22:29 ч. UTC

Печалби

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14.11.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

14.11.2025 г., 21:18 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14.11.2025 г., 20:27 ч. UTC

Пазарно говорене

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14.11.2025 г., 20:23 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14.11.2025 г., 20:17 ч. UTC

Придобивния, сливания и поглъщания

Several State Attorneys General Oppose Railroad Merger -- WSJ

14.11.2025 г., 19:29 ч. UTC

Пазарно говорене

Печалби

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14.11.2025 г., 18:44 ч. UTC

Пазарно говорене

Печалби

Disney's Growth Now Hinges More on ESPN -- Market Talk

14.11.2025 г., 18:27 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.11.2025 г., 18:27 ч. UTC

Пазарно говорене

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14.11.2025 г., 18:20 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Печалби

Auto & Transport Roundup: Market Talk

14.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

14.11.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

14.11.2025 г., 16:51 ч. UTC

Пазарно говорене

Starbucks Gets Holiday Sales Lift -- Market Talk

14.11.2025 г., 16:48 ч. UTC

Пазарно говорене

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14.11.2025 г., 16:38 ч. UTC

Пазарно говорене

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14.11.2025 г., 16:30 ч. UTC

Придобивния, сливания и поглъщания

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14.11.2025 г., 16:28 ч. UTC

Пазарно говорене

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

14.11.2025 г., 15:59 ч. UTC

Пазарно говорене

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

14.11.2025 г., 15:06 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

14.11.2025 г., 15:06 ч. UTC

Пазарно говорене

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Cogent Biosciences Inc Прогноза

Ценова цел

By TipRanks

20.13% нагоре

12-месечна прогноза

Среден 40.64 USD 20.13%

Висок 65 USD

Нисък 20 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Cogent Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Cogent Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

4.88 / 5.87Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.